Robert M. Wenham, MD, MS, FACOG, FACS

BOARD CERTIFICATION:
          •  Gynecologic Oncology

FELLOWSHIP:
          •  Duke University Medical Center - Gynecologic Oncology

RESIDENCY:
          •  Harvard, Brigham and Women's Hospital and Massachusetts General Hospital - Obstetrics and Gynecology

MEDICAL SCHOOL:
          •  University of Texas Southwestern Medical School - Medicine

• Marchion DC, Bicaku E, Xiong Y, Zgheib NB, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-2018. Pubmedid: 23467907.


• Secord AA, Teoh DK, Barry WT, Yu M, Broadwater G, Havrilesky LJ, Lee PS, Berchuck A, Lancaster J, Wenham RM. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. Clin Cancer Res. 2013 May;18(19):5489-5498. Pubmedid: 22837181. Pmcid: PMC3463759.


• Wenham RM, Lapolla J, Lin HY, Apte SM, Lancaster JM, Judson PL, Gonzalez-Bosquet J, Herschberger A, Havrilesky LJ, Secord AA. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. Gynecol Oncol. 2013 Apr;130(1):19-24. Pubmedid: 23623830.


• Teefey P, Zgheib NB, Apte SM, Gonzalez-Bosquet J, Judson PL, Roberts WS, Lancaster JM, Wenham RM. Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers. Am J Obstet Gynecol. 2013 Mar;208(6):501.e1-501.e7. Pubmedid: 23507546.


• Jim HS, Jacobsen PB, Phillips KM, Wenham RM, Roberts W, Small BJ. Lagged Relationships Among Sleep Disturbance, Fatigue, and Depressed Mood During Chemotherapy. Health Psychol. 2013 Feb. Pubmedid: 23437852.


• Xu CX, Xu M, Tan L, Yang H, Permuth-Wey J, Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA, Cheng JQ. MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J Biol Chem. 2012 Dec;287(42):34970-34978. Pubmedid: 22927443. Pmcid: PMC3471722.


• Zgheib NB, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM. The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. Int J Oncol. 2012 Aug;41(1):179-188. Pubmedid: 22552627.


• Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM. In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Br J Cancer. 2012 Aug;106(12):1967-1975. Pubmedid: 22596241. Pmcid: PMC3388569.


• Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, Sawah EA, Wenham RM, Apte SM, Gonzalez-Bosquet J, Judson PL, Hakam A, Lancaster JM. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J Gynecol Oncol. 2012 Aug;23(1):35-42. Pubmedid: 22355465. Pmcid: PMC3280065.


• Judson PL, Al Sawah E, Marchion DC, Xiong Y, Bicaku E, Zgheib NB, Chon HS, Stickles XB, Hakam A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Chen DT, Lancaster JM. Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity. Int J Gynecol Cancer. 2012 Jul;22(6):960-967. Pubmedid: 22740002.


• Chon HS, Marchion DC, Xiong Y, Chen N, Bicaku E, Stickles XB, Zgheib NB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Lancaster JM. The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecol Oncol. 2012 Jan;124(1):119-124. Pubmedid: 22032837.


• Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs. 2011 Dec;29(6):1381-1389. Pubmedid: 20644979.


• Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res. 2011 Oct;17(19):6356-6366. Pubmedid: 21849418. Pmcid: PMC3186862.


• Wenham RM. Ovarian cancer: a bright future. Cancer Control. 2011 Jan;18(1):4-5. Pubmedid: 21273974.


• Indermaur MD, Xiong Y, Kamath SG, Boren T, Hakam A, Wenham RM, Apte SM, Lancaster JM. Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin. Am J Obstet Gynecol. 2010 Aug;203(2):158.e1-158.40. Pubmedid: 20444440.


• Kamath SG, Chen N, Xiong Y, Wenham R, Apte S, Humphrey M, Cragun J, Lancaster JM. Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation. Int J Gynecol Cancer. 2009 Dec;19(9):1564-1569. Pubmedid: 19955938.


• Bansal N, Roberts WS, Apte SM, Lancaster JM, Wenham RM. Electrothermal bipolar coagulation decreases the rate of red blood cell transfusions for pelvic exenterations. J Surg Oncol. 2009 Nov;100(6):511-514. Pubmedid: 19697350.


• Hoffman MS, Ondrovic LE, Wenham RM, Apte SM, Shames ML, Zervos EE, Weinberg WS, Roberts WS. Evaluation of the porcine model to teach various ancillary procedures to gynecologic oncology fellows. Am J Obstet Gynecol. 2009 Jul;201(1):116.e1-116.e3. Pubmedid: 19576378.


• Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster JM. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 2009 Apr;113(2):249-255. Pubmedid: 19237188.


• Hakim AA, Barry CP, Barnes HJ, Anderson KE, Petitte J, Whitaker R, Lancaster JM, Wenham RM, Carver DK, Turbov J, Berchuck A, Kopelovich L, Rodriguez GC. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. Cancer Prev Res (Phila). 2009 Feb;2(2):114-121. Pubmedid: 19174584.


• Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009 Jan;16(1):8-13. Pubmedid: 19078924.


• Marquez CB, Smithberger EE, Bair SM, Wenham RM, Fenske NA, Glass LF, Cherpelis BS. Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene. Cancer Control. 2009 Jan;16(1):66-69. Pubmedid: 19078932.


• Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen D, Dressman H, Lancaster J. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol. 2008 Aug;110(2):206-215. Pubmedid: 18499237.


• Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008 Jan;68(2):425-433. Pubmedid: 18199536.


• Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007 Nov;25(33):5180-5186. Pubmedid: 18024865.


• Hoyo C, Grubber J, Demark-Wahnefried W, Marks JR, Freedland SJ, Jeffreys AS, Grambow SC, Wenham RM, Walther PJ, Schildkraut JM. Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites. J Natl Med Assoc. 2007 Jul;99(7):718-722. Pubmedid: 17668637.


• Donovan K, Taliaferro L, Alvarez E, Jacobsen P, Roetzheim R, Wenham R. Sexual health in women treated for cervical cancer: Characteristics and correlates. Gynecol Oncol. 2007 Feb;104(2):428-434. Pubmedid: 17005248.


• Berchuck A, Schildkraut JM, Wenham RM, Calingaert B, Ali S, Henriott A, Halabi S, Rodriguez GC, Gertig D, Purdie DM, Kelemen L, Spurdle AB, Marks J, Chenevix-Trench G. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2141-2147. Pubmedid: 15598772.


• Wenham R, Calingaert B, Ali S, McClean K, Whitaker R, Bentley R, LancasterJM, Schildkraut J, Marks J, Berchuck A. Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovariancancer. J Soc Gynecol Investig. 2003;10:381-387. Pubmedid: 12969782.


• Wenham R, Schildkraut J, McLean K, Calingaert B, Bentley R, Marks J, Berchuck A. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res. 2003;9(12):4396-4403. Pubmedid: 14555511.


• Garrett A, Wenham R, Sheets E. Monsel's Solution: A Brief History. J Low Genit Tract Dis. 2002 Oct;6(4):225-227. Pubmedid: 17051027.


• Garrett A, Wenham R, Onderdonk A, Sheets E. Can Monsel's Transmit Nosocomial Infections? A Microbiological Investigation. J Low Genit Tract Dis. 2002 Oct;6(4):228-231. Pubmedid: 17051028.


• Wenham R, Lancaster J, Berchuck A. Molecular aspects of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2002;16(4):483-497. Pubmedid: 12413930.


• Lea J, Sheets E, Wenham R, Duska L, Coleman R, Miller D, Schorge J. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol. 2002;84(1):115-119. Pubmedid: 11748986.


• Wenham RM, Landt M, Walters SM, Hidaka H, Easom RA. Inhibition of insulin secretion by KN-62, a specific inhibitor of the multifunctional Ca2+/calmodulin-dependent protein kinase II. Biochem Biophys Res Commun. 1992 Nov;189(1):128-133. Pubmedid: 1333187.


• Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. Cancer J. 17(6):528-536. Pubmedid: 22157297. Pmcid: PMC3240816.

Dr. Robert Wenham is a gynecologic oncologist in The Center for Women’s Oncology at Moffitt Cancer Center. Dr. Wenham also serves as the medical director of the Moffitt Clinical Research Network.

Dr. Wenham has a strong interest in research and is a principal investigator for the Gynecologic Oncology Group (GOG), the premier national organization developing clinical trials to improve cancer care for women.  He is also the principal investigator for Total Cancer Care, Moffitt’s unique approach to developing targeted, personalized treatment for each cancer patient.  His research activities include identifying markers that can predict patients’ response to treatments.  He received a Molly Cade Ovarian Cancer Research Award from the Gynecologic Cancer Foundation. 

Dr. Wenham enjoys the challenge of helping women with complex issues and the opportunity to offer them cutting-edge therapies, from the latest chemotherapy approaches to biological targeted therapies, minimally invasive surgery and clinical trials.  Moffitt’s pioneering research gives patients the opportunity to benefit from tomorrow’s medicine today.

The future of gyn oncology is exciting as the rapid pace of translational research is changing the outcome and quality of life for patients.  Dr. Wenham points out that life expectancy for certain women’s cancers, such as ovarian cancer, have dramatically improved over the last 30 years and continue to improve at an encouraging rate.

Dr. Wenham also sees patients at Moffitt Cancer Center at International Plaza.